Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates

分组1 - Assembly Biosciences reported quarterly earnings of $2.48 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.51 per share, representing an earnings surprise of +586.28% [1] - The company posted revenues of $42.47 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 300.65%, compared to revenues of $7.36 million a year ago [2] - Over the last four quarters, Assembly Biosciences has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 19.1% since the beginning of the year, while the S&P 500 has declined by 3.2% [3] - The current consensus EPS estimate for the coming quarter is -$0.50 on revenues of $10.6 million, and for the current fiscal year, it is -$4.10 on revenues of $32.2 million [7] - The Zacks Industry Rank for Medical - Generic Drugs is currently in the bottom 23% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8]